| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 01/16/2003 | WO2003004639A1 Dna fragments containing gene having function relating to autonomous proliferation of plasmid |
| 01/16/2003 | WO2003004637A1 Utilization of histamine receptor h3 gene participating in body weight or food intake control |
| 01/16/2003 | WO2003004631A2 USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |
| 01/16/2003 | WO2003004627A2 Novel human hepatoma lines, methods for obtaining same and uses thereof |
| 01/16/2003 | WO2003004623A2 Human secreted proteins |
| 01/16/2003 | WO2003004622A2 Human secreted proteins |
| 01/16/2003 | WO2003004620A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004618A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/16/2003 | WO2003004617A2 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004613A2 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | WO2003004611A2 Human olfactory nucleotide-gated ion channels |
| 01/16/2003 | WO2003004610A2 Hsst and angiogenesis |
| 01/16/2003 | WO2003004609A2 Novel human kielin-like proteins and polynucleotides encoding the same |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004601A2 New assays for preimplantation factor and preimplantation factor peptides |
| 01/16/2003 | WO2003004600A2 Improvement of viral uptake into cells and tissues |
| 01/16/2003 | WO2003004532A2 Q9ul33/q9nzz4 and q9h5p3 splice variants |
| 01/16/2003 | WO2003004531A2 Regulation of human somatostatin receptor-like protein |
| 01/16/2003 | WO2003004530A1 Regulation of human somatostatin receptor-like protein |
| 01/16/2003 | WO2003004529A2 Ephrin-tie receptor materials and methods |
| 01/16/2003 | WO2003004528A1 Human g protein-coupled receptors and uses thereof |
| 01/16/2003 | WO2003004527A2 Novel neurotrophic factors |
| 01/16/2003 | WO2003004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines |
| 01/16/2003 | WO2003004525A2 Isolation and purification of plasmodium falciparum merozoite protein-142 |
| 01/16/2003 | WO2003004524A2 Apicomplexa parasites secreted proteins |
| 01/16/2003 | WO2003004523A1 Regulation of human citron rho/rac-interacting kinase |
| 01/16/2003 | WO2003004521A2 Nucleotide sequence and method for increasing the resistance to disease in plants |
| 01/16/2003 | WO2003004520A2 Mycobacterial antigens expressed during latency |
| 01/16/2003 | WO2003004519A1 Icosahedral superstructures of vp2 of infectious bursitis virus (ibdv) and the applications thereof |
| 01/16/2003 | WO2003004518A2 Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors |
| 01/16/2003 | WO2003004517A2 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | WO2003004514A1 Small intestine and colon genes |
| 01/16/2003 | WO2003004466A2 Dye-sulfenates for dual phototherapy |
| 01/16/2003 | WO2003004091A2 Aromatic sulfenates for type i phototherapy |
| 01/16/2003 | WO2003004067A1 Methods and compositions for the treatment and diagnosis of body weight disorders |
| 01/16/2003 | WO2003004066A1 Gene therapeutics |
| 01/16/2003 | WO2003004065A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 01/16/2003 | WO2003004063A1 Genetically engineered therapy method for treating gnrh receptor-positive carcinoma by gnrh-induced tumor cell-specific activation of a therapeutic gene, corresponding nucleic acid constructs and vectors |
| 01/16/2003 | WO2003004061A1 Uv-screening peptide-flavonoid conjugates |
| 01/16/2003 | WO2003004050A1 Methylation of histone h4 at arginine 3 |
| 01/16/2003 | WO2003004047A1 Cell death inducers for mast cells |
| 01/16/2003 | WO2003004006A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | WO2003003988A2 Peptides which modulate blood coagulation and methods of use thereof |
| 01/16/2003 | WO2003003984A2 Novel proteins and nucleic acids encoding same |
| 01/16/2003 | WO2003003983A2 Receptor agonists useful for the treatment of pain |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003977A2 Compositions and methods for the treatment of body weight disorders, including obesity |
| 01/16/2003 | WO2003003906A2 Diagnostic and screening methods for bladder cancer |
| 01/16/2003 | WO2003003904A2 Coactivators in the diagnosis and treatment of breast cancer |
| 01/16/2003 | WO2003003838A1 Method of enhancing the extraction of proteinase inhibitors |
| 01/16/2003 | WO2003003837A1 Isolation and purification of proteinase inhibitor ii |
| 01/16/2003 | WO2003003836A1 Method for the elimination of kunitz and bowman-birk trypsin inhibitors and carboxydase inhibitor from potato proteins |
| 01/16/2003 | WO2003003835A1 Method for controlling the yield and purity of proteinase inhibitor ii during extraction |
| 01/16/2003 | WO2003003824A1 Potential-dependent ca2+ channel a1b knockout non-human animal |
| 01/16/2003 | WO2002089764A3 Gelatin substitute |
| 01/16/2003 | WO2002088178A3 Antigens of group b streptococcus and corresponding dna fragments |
| 01/16/2003 | WO2002082081A3 Suppression of androgen receptor transactivation through new pathways to ar and ar coactivators and repressors |
| 01/16/2003 | WO2002077026A3 Gene involved in v(d)j recombination and/or dna repair |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002070690A3 Abca5 transporter and uses thereof |
| 01/16/2003 | WO2002067968A3 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 01/16/2003 | WO2002066510A3 Regakine-1 |
| 01/16/2003 | WO2002062379A3 Clostridium difficile vaccine |
| 01/16/2003 | WO2002059148A8 A method for identification, isolation and production of antigens to a specific pathogen |
| 01/16/2003 | WO2002059147A3 Activatable cytolytic or drug delivery peptides and uses thereof |
| 01/16/2003 | WO2002053712A3 Avian hepatitis e virus, vaccines and methods of protecting against avian hepatitis-splenomegaly syndrome and mammalian hepatitis e |
| 01/16/2003 | WO2002053701A3 Epididymal lipocalin gene and uses thereof |
| 01/16/2003 | WO2002046362A3 Gene associated with benign prostatic hyperplasia in humans |
| 01/16/2003 | WO2002046223A3 Compositions and methods related to the minn1 tumor suppressor gene and protein |
| 01/16/2003 | WO2002040633A3 Optimized antitrypsin expression in rice cell culture |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002038587A3 Haplotypes of the grm8 gene |
| 01/16/2003 | WO2002038177A3 Adjuvant combination formulations |
| 01/16/2003 | WO2002034771A3 Nucleic acids and proteins from streptococcus groups a & b |
| 01/16/2003 | WO2002034769A3 Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 |
| 01/16/2003 | WO2002033081A3 Veterinary immunisation vectors comprising nucleic acid sequences encoding variants of non-human c3d polypeptides |
| 01/16/2003 | WO2002032286A3 Protein-protein interactions in neurodegenerative diseases |
| 01/16/2003 | WO2002031144A3 Identification of cytotoxic activity from the ink of aplysia punctata |
| 01/16/2003 | WO2002029030A3 Ethanol production |
| 01/16/2003 | WO2002026819A3 Recombinant bcg vaccines for the prevention and treatment of cancer |
| 01/16/2003 | WO2002022808A3 Cripto mutant and uses thereof |
| 01/16/2003 | WO2002022806A3 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 01/16/2003 | WO2002022080A8 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 01/16/2003 | WO2002021141A3 Methods and compositions for diseases associated with amyloidosis |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | WO2002018584A3 Xage-1, a gene expressed in multiple cancers, and uses thereof |
| 01/16/2003 | WO2002018546A3 Plasma-derived-fibrin-based matrices and tissue |
| 01/16/2003 | WO2002016595A3 Kidney-specific protein |
| 01/16/2003 | WO2002016587A3 Microtubule-associated proteins and tubulins |
| 01/16/2003 | WO2002016578A3 Secreted proteins and methods of using same |
| 01/16/2003 | WO2002014352A3 Therapeutic compounds for ovarian cancer |
| 01/16/2003 | WO2002010406A3 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 01/16/2003 | WO2002010200A3 Pas domain proteins |
| 01/16/2003 | WO2002008280A3 SCREENING METHODS BASED ON SUPERACTIVATED αVβ3 INTEGRIN |
| 01/16/2003 | WO2002008275A3 Genes expressed in obese rat hypothalamus |
| 01/16/2003 | WO2002002772A3 Human extracellular matrix (ecm)-related tumor marker |
| 01/16/2003 | WO2002002604A3 Leucine-rich repeat proteins, zlrr7, zlrr8 and zlrr9 |